Respira Therapeutics is developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung. Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be —in the lung and lung periphery, instead of in the oropharyngeal cavity. Respira’s lead product candidate, RT234-PAH, has received FDA Orphan Drug Designation for Pulmonary Arterial Hypertension and is in Phase 2 clinical trials as a first-in-class inhaled therapeutic for as-needed use to provide acute relief for the most commonly reported symptoms in PAH patients.
Company Details
- Employees
- 15
- Founded
- -
- Address
- Middlefield Rd, Palo Alto,california,united States
- Phone
- 5058201832
- rc****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- respiratherapeutics.com
- HQ
- Palo Alto, California
Respira Therapeutics, Inc. Questions
Respira Therapeutics, Inc.'s helpline number is 5058201832
Respira Therapeutics, Inc.'s website is respiratherapeutics.com
Respira Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/respira-therapeutics
Respira Therapeutics, Inc. has
15 employees.
View email and phone details for 15
employees at Respira Therapeutics, Inc..
Respira Therapeutics, Inc.'s industry is
Biotechnology Research
Respira Therapeutics, Inc.'s top competitors are
Lung Therapeutics,
Sarepta Therapeutics,
Jade Biosciences,
Spyglass Pharma, Inc.,
Qnovia, Inc.,
Kura Oncology, Inc.,
Pathalys Pharma,
Spruce Biosciences,
Avalyn Pharma,
Rein Therapeutics.
Respira Therapeutics, Inc.'s support email address is rcurtis@respiratherapeutics.com
Respira Therapeutics, Inc.'s categories are Biotechnology Research
Respira Therapeutics, Inc.'s founding year is 2010
